Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Mahidol University
Sponsor:
Information provided by (Responsible Party):
Mahidol University
ClinicalTrials.gov Identifier:
NCT01597999
First received: May 13, 2011
Last updated: January 21, 2013
Last verified: January 2013

May 13, 2011
January 21, 2013
February 2011
July 2012   (final data collection date for primary outcome measure)
study the benefits of DCE-MRI using Gadovist in prognostic determination of early invasive breast cancer [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The benefits of breast tumor diagnosis from DCE-MRI in early invasive breast cancer with poor prognostic features
Same as current
Complete list of historical versions of study NCT01597999 on ClinicalTrials.gov Archive Site
ascertain the accuracy of pre-operative DCE-MRI in terms of detection and characterization of breast cancer, as compared to tissue biopsy. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The comparision between DCE-MRI radiological features in early invasive breast cancer with poor prognostic features and early invasive breast cancer with good prognostic features To ascertain the accuracy of pre-operative DCE-MRI in terms of detection and charecterization of breast cancer, as compared to tissue biopsy
Same as current
Not Provided
Not Provided
 
Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer
Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status

This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.

Dedicated Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)

Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Invasive Breast Cancer
Radiation: MRI
magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
Other Name: Magnetic Resonance Imaging
No treatment
Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
Intervention: Radiation: MRI
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2013
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with invasive ductal carcinoma
  • Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
  • Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
  • Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines.

Exclusion Criteria:

  • Patients under 18 years old or during pregnancy
  • Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment
Female
18 Years and older
No
Contact: Dr.Pornpim Korpraphong, Assist.Prof. 6624197000 ext 9039 pfuang@yahoo.com
Thailand
 
NCT01597999
15262, 578/2533(EC4)
No
Mahidol University
Mahidol University
Not Provided
Principal Investigator: Pornpim Korpraphong, M.D. Mahidol University
Mahidol University
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP